News | July 16, 2024
Merck completes acquisition of EyeBio
Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret
Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret
Protein research is key to advancing our understanding of human biology and delivering on the promise of precision medicine
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
Lenire is the first and only bimodal neuromodulation device to be awarded a Federal Supply Schedule (FSS) Contract from the US Government
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
Subscribe To Our Newsletter & Stay Updated
